Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials

BACKGROUND: Screening to identify individuals with elevated brain amyloid (Aβ+) for clinical trials in Preclinical Alzheimer’s Disease (PAD), such as the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) trial, is slow and costly. The Trial-Ready Cohort in Preclinical/Prodromal Alzheim...

Descripción completa

Detalles Bibliográficos
Autores principales: Langford, O., Raman, R., Sperling, R.A., Cummings, J., Sun, C.-K., Jimenez-Maggiora, G., Aisen, P.S., Donohue, M.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745538/
https://www.ncbi.nlm.nih.gov/pubmed/32920622
http://dx.doi.org/10.14283/jpad.2020.44

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745538/
https://www.ncbi.nlm.nih.gov/pubmed/32920622
http://dx.doi.org/10.14283/jpad.2020.44

Ejemplares similares